GlobeNewswire: Beleave Inc. Contains the last 10 of 34 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:12:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/03/01/1409511/0/en/Beleave-Provides-Update-on-Manitoba-Retail-Licensing-Agreement.html?f=22&fvtc=4&fvtv=28684Beleave Provides Update on Manitoba Retail Licensing Agreement2018-03-01T21:30:00Z<![CDATA[TORONTO, March 01, 2018 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE); (OTCQX:BLEVF) would like to provide an update with regard to recent retail licensing grants in the province of Manitoba. On January 3rd, 2018 the Company announced that it had signed a letter of intent with Seven Oaks of Manitoba to supply 1.25 million grams of dry cannabis flower or equivalent. The transaction was contingent on Seven Oaks’ ability to obtain a retail license from the government of Manitoba, however they did not obtain it in this round of licensing.]]>https://www.globenewswire.com/news-release/2018/01/31/1329191/0/en/Beleave-Receives-Notification-of-Pre-Sale-Inspection-Date.html?f=22&fvtc=4&fvtv=28684Beleave Receives Notification of Pre-Sale Inspection Date2018-01-31T12:35:00Z<![CDATA[TORONTO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE)(OTCQX:BLEVF) is pleased to announce that it has received notification from Health Canada that the Company's pre-sale inspection has been scheduled for February 8, 2018. The issuance of a sales license under the Access to Cannabis for Medical Purposes Regulations is in part dependent upon the completion of a satisfactory pre-sale inspection by Health Canada.]]>https://www.globenewswire.com/news-release/2018/01/03/1281466/0/en/Beleave-Signs-Letter-of-Intent-with-Seven-Oaks-Cannabis.html?f=22&fvtc=4&fvtv=28684Beleave Signs Letter of Intent with Seven Oaks Cannabis2018-01-03T12:25:00Z<![CDATA[TORONTO, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE) (OTCQX:BLEVF) is pleased to announce that it has signed a letter of intent with Seven Oaks Cannabis Inc. (“Seven Oaks”) for Seven Oaks to carry Beleave products if awarded a cannabis retail license by the Government of Manitoba (the “Manitoba Government”). Seven Oaks is interested in exploring a purchase and supply arrangement in which Beleave would supply minimum of 1.25 million grams, per annum, of dry flower equivalent of Beleave Inc. branded cannabis products.]]>https://www.globenewswire.com/news-release/2017/12/15/1262361/0/en/Beleave-Provides-Business-Update.html?f=22&fvtc=4&fvtv=28684Beleave Provides Business Update2017-12-15T01:07:49Z<![CDATA[TORONTO, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE) (OTCQX:BLEVF) is pleased to announce that it has received notification from Health Canada that, upon the Company's confirmation that the Company's production, testing, manufacturing, packaging, storing, labelling, shipping and record-keeping of product intended for sale is in compliance with the requirements of the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"), Health Canada will arrange a pre-sale inspection. The issuance of a sales license under the ACMPR is in part dependent upon the completion of a satisfactory pre-sale inspection by Health Canada.]]>https://www.globenewswire.com/news-release/2017/12/07/1247393/0/en/Beleave-Signs-Brand-Licensing-Agreement-with-Kevin-Smith-Jason-Mewes.html?f=22&fvtc=4&fvtv=28684Beleave Signs Brand Licensing Agreement with Kevin Smith & Jason Mewes2017-12-07T12:45:00Z<![CDATA[TORONTO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE) (OTCQX:BLEVF) is pleased to announce that it has entered into a Brand Licensing Agreement with Kevin Smith and Jason Mewes, better known as their onscreen characters, Jay and Silent Bob. Under the agreement the Company, in partnership with Kevin Smith and Jason Mewes, will be developing various proprietary strains geared towards the recreational market which will be available under the Beleave Kannabis brand.]]>https://www.globenewswire.com/news-release/2017/12/05/1229511/0/en/Beleave-Closes-9-95-Million-Non-Brokered-Private-Placement-of-Units.html?f=22&fvtc=4&fvtv=28684Beleave Closes $9.95 Million Non-Brokered Private Placement of Units2017-12-05T23:37:21Z<![CDATA[TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE) (OTCQX:BLEVF) is pleased to announce the completion of a non-brokered private placement (the "Non-Brokered Offering") of units of the Company at a price of $1.50 per unit for aggregate gross proceeds of approximately $9.95 million.]]>https://www.globenewswire.com/news-release/2017/12/04/1220334/0/en/Beleave-Receives-License-to-Produce-Cannabis-Oils-from-Health-Canada.html?f=22&fvtc=4&fvtv=28684Beleave Receives License to Produce Cannabis Oils from Health Canada2017-12-04T23:18:26Z<![CDATA[TORONTO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE)( OTCQX:BLEVF) is pleased to announce it has been granted a license by Health Canada to begin commercial production of cannabis oils.]]>https://www.globenewswire.com/news-release/2017/11/20/1197382/0/en/Beleave-Announces-5-Million-Non-Brokered-Private-Placement-of-Units.html?f=22&fvtc=4&fvtv=28684Beleave Announces $5 Million Non-Brokered Private Placement of Units2017-11-20T12:25:00Z<![CDATA[TORONTO, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE) (OTCQX:BLEVF) is pleased to announce its intention to complete a non-brokered private placement (the "Non-Brokered Offering") of up to 3,333,334 units of the Company at a price of $1.50 per unit for gross proceeds of approximately $5 million. The Company has already received sufficient interest from individuals to complete the $5 million financing. The Company may, as a result, increase the size of the Non-Brokered Offering by up to 20%, for aggregate gross proceeds of approximately $6 million.]]>https://www.globenewswire.com/news-release/2017/11/10/1184563/0/en/Beleave-Supports-Recent-Council-Decision-and-Continues-Expansion-Uninterrupted.html?f=22&fvtc=4&fvtv=28684Beleave Supports Recent Council Decision and Continues Expansion Uninterrupted2017-11-10T12:30:00Z<![CDATA[TORONTO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. (“Beleave”) (CSE:BE) (OTCQX:BLEVF) strongly supports The City of Hamilton council’s decision to turn down the motion for any new restrictions pertaining to the land use planning framework for the cannabis industry. The company continues to move forward with its facility expansion in the community of Flamborough, in the city of Hamilton, Ontario, for which it has engaged Havecon North America Inc., subsidiary of Havecon Kassenbouw, a leading Dutch-based greenhouse builder.]]>https://www.globenewswire.com/news-release/2017/10/24/1152252/0/en/Beleave-and-Dr-Michael-Rogers-Begin-Research-in-Cannabis-Food-and-Drug-Delivery.html?f=22&fvtc=4&fvtv=28684Beleave and Dr. Michael Rogers Begin Research in Cannabis Food and Drug Delivery2017-10-24T11:30:00Z<![CDATA[TORONTO, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. (“Beleave”) (CSE:BE) (OTCQX:BLEVF) is pleased to announce that it will begin a research program with Dr. Michael Rogers to develop and characterize the bioavailability of novel cannabinoid food and drug delivery systems for oral administration using lipid-based nano-systems. Dr. Rogers is an Associate Professor in the Department of Food Sciences at the University of Guelph, and the holder of a Canada Research Chair in Food Nanotechnology.]]>